Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis

Pamela K Foreman1, Andrea V Margulis2, Kimberly Alexander1

  • 1BioMarin Pharmaceutical Inc, 770 Lindaro Street, San Rafael, CA, 94901, USA.

Insights

Phenylalanine hydroxylase (PAH) deficiency, an autosomal recessive disorder, has a global birth prevalence of 0.64 per 10,000 births. Significant regional variations exist, highlighting the need for tailored newborn screening strategies for this condition.

Area of Science:

  • Genetics and Genetic Disorders
  • Metabolic Disorders
  • Public Health and Epidemiology

Background:

  • Phenylalanine hydroxylase (PAH) deficiency is an inherited metabolic disorder causing elevated blood phenylalanine (Phe) levels.
  • Untreated PAH deficiency can lead to severe neurocognitive impairment.
  • Newborn screening is crucial for early detection and management of PAH deficiency.

Purpose of the Study:

  • To estimate the global birth prevalence of PAH deficiency using newborn screening data.
  • To analyze regional variations in PAH deficiency prevalence.
  • To assess prevalence based on different phenylalanine (Phe) cutoff values used in confirmatory testing.

Main Methods:

  • Systematic literature review and meta-analysis of newborn screening studies.
  • Searches conducted in PubMed and Embase databases.
  • Inclusion of studies reporting numeric birth prevalence of confirmed PAH deficiency.

Main Results:

  • A global birth prevalence of 0.64 per 10,000 births was estimated (95% CI 0.53-0.75).
  • Prevalence varied significantly by region, from 0.03 in Southeast Asia to 1.18 in the Middle East/North Africa.
  • Prevalence estimates differed based on Phe cutoff values: 0.96 (360 µmol/L), 0.50 (600 µmol/L), and 0.30 (1200 µmol/L).

Conclusions:

  • Substantial regional disparities in PAH deficiency birth prevalence were identified.
  • The precision of prevalence estimates is constrained by sample sizes, even with widespread newborn screening.
  • Further research may be needed to refine prevalence estimates and understand regional variations.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
442
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
44
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Pedigree Analysis01:35

Pedigree Analysis

Overview
86.7K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
71
Probability Laws01:49

Probability Laws

Overview
42.5K